Albrecht T, Schnorr B, Kutschera M, Waliszewski MW. Two-Year Mortality After Angioplasty of the Femoro-Popliteal Artery with Uncoated Balloons and Paclitaxel-Coated Balloons-A Pooled Analysis of Four Randomized Controlled Multicenter Trials. Cardiovasc Intervent Radiol. 2019;42(7):949–55.
Caradu C, Lakhlifi E, Colacchio EC, Midy D, Berard X, Poirier M, et al. Systematic review and updated meta-analysis of the use of drug-coated balloon angioplasty versus plain old balloon angioplasty for femoropopliteal arterial disease. J Vasc Surg. 2019;70(3):981-95.e10.
Feng H, Chen X, Guo X, Zhang Z, Zhang Z, Liu B, et al. Comparison of efficacy and safety of drug-eluting versus uncoated balloon angioplasty for femoropopliteal arterial occlusive disease: a meta-analysis. BMC Cardiovasc Disord. 2020;20(1):395.
CAS PubMed PubMed Central Article Google Scholar
Tepe G, Laird J, Schneider P, Brodmann M, Krishnan P, Micari A, et al. Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN PACT SFA randomized trial. Circulation. 2015;131(15):495–502.
CAS PubMed PubMed Central Article Google Scholar
Tepe G, Zeller T, Albrecht T, Heller S, Schwarzwalder U, Beregi JP, et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med. 2008;358(7):689–99.
CAS PubMed Article Google Scholar
Ullah W, Zghouzi M, Sattar Z, Ahmad B, Zahid S, Suleiman AM, et al. Safety and efficacy of drug-coated balloon for peripheral artery revascularization-A systematic review and meta-analysis. Catheter Cardiovasc Interv. 2022;99(4):1319–26.
Werk M, Albrecht T, Meyer DR, Ahmed MN, Behne A, Dietz U, et al. Paclitaxel-coated balloons reduce restenosis after femoro-popliteal angioplasty: evidence from the randomized PACIFIER trial. Circ Cardiovasc Interv. 2012;5(6):831–40.
CAS PubMed Article Google Scholar
Werk M, Langner S, Reinkensmeier B, Boettcher HF, Tepe G, Dietz U, et al. Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial. Circulation. 2008;118(13):1358–65.
CAS PubMed Article Google Scholar
Aboyans V, Ricco JB, Bartelink MEL, Bjorck M, Brodmann M, Cohnert T, et al. 2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the european society for vascular surgery (ESVS). Rev Esp Cardiol (Engl Ed). 2018;71(2):111.
Schlager O, Gschwandtner ME, Willfort-Ehringer A, Wolf F, Loewe C, Koppensteiner R, et al. Drug coated balloons in the superficial femoral artery. J Cardiovasc Surg (Torino). 2018;59(1):60–9.
Granada JF, Stenoien M, Buszman PP, Tellez A, Langanki D, Kaluza GL, et al. Mechanisms of tissue uptake and retention of paclitaxel-coated balloons: impact on neointimal proliferation and healing. Open Heart. 2014;1(1):e000117.
PubMed PubMed Central Article Google Scholar
Murphy GJ, Johnson TW, Chamberlain MH, Rizvi SI, Wyatt M, George SJ, et al. Short- and long-term effects of cytochalasin D, paclitaxel and rapamycin on wall thickening in experimental porcine vein grafts. Cardiovasc Res. 2007;73(3):607–17.
CAS PubMed Article Google Scholar
Speck U, Hackel A, Schellenberger E, Kamann S, Lochel M, Clever YP, et al. Drug distribution and basic pharmacology of paclitaxel/resveratrol-coated balloon catheters. Cardiovasc Intervent Radiol. 2018;41(10):1599–610.
PubMed PubMed Central Article Google Scholar
Gemeinhardt O, Schnorr B, Speck U, Scheller B. A novel paclitaxel coated balloon with increased drug transfer for treatment of complex vascular lesions. PLoS ONE. 2021;16(10):e0259106.
CAS PubMed PubMed Central Article Google Scholar
Jeger RV, Eccleshall S, Wan Ahmad WA, Ge J, Poerner TC, Shin ES, et al. Drug-coated balloons for coronary artery disease: third report of the international DCB consensus group. JACC Cardiovasc Interv. 2020;13(12):1391–402.
Cassese S, Ndrepepa G, Fusaro M, Kufner S, Xhepa E, Fusaro M. Paclitaxel density and clinical efficacy of drug-coated balloon angioplasty for femoropopliteal artery disease: meta-analysis and adjusted indirect comparison of 20 randomised trials. EuroIntervention. 2019;15(6):e560–2.
Kelsch B, Scheller B, Biedermann M, Clever YP, Schaffner S, Mahnkopf D, et al. Dose response to paclitaxel-coated balloon catheters in the porcine coronary overstretch and stent implantation model. Invest Radiol. 2011;46(4):255–63.
CAS PubMed Article Google Scholar
Scheller B, Speck U, Abramjuk C, Bernhardt U, Bohm M, Nickenig G. Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis. Circulation. 2004;110(7):810–4.
CAS PubMed Article Google Scholar
Giacoppo D, Cassese S, Harada Y, Colleran R, Michel J, Fusaro M, et al. Drug-coated balloon versus plain balloon angioplasty for the treatment of femoropopliteal artery disease: an updated systematic review and meta-analysis of randomized clinical trials. JACC Cardiovasc Interv. 2016;9(16):1731–42.
Katsanos K, Spiliopoulos S, Paraskevopoulos I, Diamantopoulos A, Karnabatidis D. Systematic review and meta-analysis of randomized controlled trials of paclitaxel-coated balloon angioplasty in the femoropopliteal arteries: role of paclitaxel dose and bioavailability. J Endovasc Ther. 2016;23(2):356–70.
Laird JA, Schneider PA, Jaff MR, Brodmann M, Zeller T, Metzger DC, et al. Long-term clinical effectiveness of a drug-coated balloon for the treatment of femoropopliteal lesions. Circ Cardiovasc Interv. 2019;12(6):e007702.
CAS PubMed PubMed Central Article Google Scholar
Lookstein RA, Haruguchi H, Ouriel K, Weinberg I, Lei L, Cihlar S, et al. Drug-coated balloons for dysfunctional dialysis arteriovenous fistulas. N Engl J Med. 2020;383(8):733–42.
CAS PubMed Article Google Scholar
Tepe G, Schroeder H, Albrecht T, Reimer P, Diehm N, Baeriswyl JL, et al. Paclitaxel-coated balloon vs uncoated balloon angioplasty for treatment of in-stent restenosis in the superficial femoral and popliteal arteries: The COPA CABANA trial. J Endovasc Ther. 2020;27(2):276–86.
Bettink S, Lochel M, Peters D, Haider W, Speck U, Scheller B. Efficacy and safety of a magnesium stearate paclitaxel coated balloon catheter in the porcine coronary model. Int J Cardiol. 2021;331:46–56.
Schwartz RS, Huber KC, Murphy JG, Edwards WD, Camrud AR, Vlietstra RE, et al. Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model. J Am Coll Cardiol. 1992;19(2):267–74.
CAS PubMed Article Google Scholar
Kornowski R, Hong MK, Tio FO, Bramwell O, Wu H, Leon MB. In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. J Am Coll Cardiol. 1998;31(1):224–30.
CAS PubMed Article Google Scholar
Steiner S, Schmidt A, Zeller T, Tepe G, Thieme M, Maiwald L, et al. COMPARE: prospective, randomized, non-inferiority trial of high- vs. low-dose paclitaxel drug-coated balloons for femoropopliteal interventions. Eur Heart J. 2020;41(27):2541–52.
CAS PubMed PubMed Central Article Google Scholar
Trerotola SO, Saad TF, Roy-Chaudhury P. The Lutonix AV randomized trial of paclitaxel-coated balloons in arteriovenous fistula stenosis: 2year results and subgroup analysis. J Vasc Interv Radiol. 2020;31(1):1-14.e5.
Vazquez-Padron RI, Duque JC, Tabbara M, Salman LH, Martinez L. Intimal hyperplasia and arteriovenous fistula failure: looking beyond size differences. Kidney360. 2021;2(8):1360–72.
PubMed PubMed Central Article Google Scholar
Abadal JM, Vazquez E, Morales M, Toro A, Quintana M, Araujo M. Pharmacokinetic evaluation of two paclitaxel-coated balloons with different drug load in a short-term porcine study. Cardiovasc Interve Radiol. 2016;39(8):1152–8.
Torii S, Jinnouchi H, Sakamoto A, Romero ME, Kolodgie FD, Virmani R, et al. Comparison of biologic effect and particulate embolization after femoral artery treatment with three drug-coated balloons in healthy swine model. J Vasc Interv Radiol. 2019;30(1):103–9.
Yazdani SK, Pacheco E, Nakano M, Otsuka F, Naisbitt S, Kolodgie FD, et al. Vascular, downstream, and pharmacokinetic responses to treatment with a low dose drug-coated balloon in a swine femoral artery model. Catheter Cardiovasc Interv. 2014;83(1):132–40.
Clever YP, Peters D, Calisse J, Bettink S, Berg MC, Sperling C, et al. Novel sirolimus-coated balloon catheter: in vivo evaluation in a porcine coronary model. Circ Cardiovasc Interv. 2016;9(4):e003543.
CAS PubMed Article Google Scholar
Katsanos K, Spiliopoulos S, Kitrou P, Krokidis M, Karnabatidis D. Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. 2018;7(24):e011245.
PubMed PubMed Central Article Google Scholar
Bohme T, Noory E, Beschorner U, Jacques B, Burgelin K, Macharzina R, et al. Evaluation of mortality following paclitaxel drug-coated balloon angioplasty of femoropopliteal lesions in the real world. JACC Cardiovasc Interv. 2020;13(17):2052–61.
Donas KP, Sohr A, Pitoulias GA, Alfonso F, Torsello G. Long-Term mortality of matched patients with intermittent claudication treated by high-dose paclitaxel-coated balloon versus plain balloon angioplasty: a real-world study. Cardiovasc Interve Radiol. 2020;43(1):2–7.
Freisinger E, Koeppe J, Gerss J, Goerlich D, Malyar NM, Marschall U, et al. Mortality after use of paclitaxel-based devices in peripheral arteries: a real-world safety analysis. Eur Heart J. 2020;41(38):3732–9.
留言 (0)